11.50
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAPR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.81
Aprire:
$11.79
Volume 24 ore:
1.19M
Relative Volume:
1.06
Capitalizzazione di mercato:
$525.28M
Reddito:
$27.10M
Utile/perdita netta:
$-24.31M
Rapporto P/E:
-13.86
EPS:
-0.83
Flusso di cassa netto:
$-33.33M
1 W Prestazione:
-10.58%
1M Prestazione:
-20.03%
6M Prestazione:
+15.58%
1 anno Prestazione:
+69.37%
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Nome
Capricor Therapeutics Inc
Settore
Industria
Telefono
(310) 358-3200
Indirizzo
8840 WILSHIRE BLVD, BEVERLY HILLS, CA
Confronta CAPR con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
CAPR
Capricor Therapeutics Inc
|
11.50 | 525.28M | 27.10M | -24.31M | -33.33M | -0.83 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-10-21 | Iniziato | Piper Sandler | Overweight |
2024-05-17 | Iniziato | Oppenheimer | Outperform |
2024-01-05 | Iniziato | Cantor Fitzgerald | Overweight |
2022-10-26 | Iniziato | Ladenburg Thalmann | Buy |
2018-12-26 | Downgrade | Maxim Group | Buy → Hold |
2018-01-26 | Reiterato | H.C. Wainwright | Buy |
2017-09-15 | Reiterato | H.C. Wainwright | Buy |
2017-02-13 | Ripresa | Rodman & Renshaw | Buy |
2016-07-06 | Ripresa | H.C. Wainwright | Buy |
2016-06-15 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie
New Forecasts: Here's What Analysts Think The Future Holds For Capricor Therapeutics, Inc. (NASDAQ:CAPR) - Simply Wall St
Check Out What Whales Are Doing With CAPR - Benzinga
High Growth Tech Stocks In The US Market With Promising Potential - Simply Wall St
(CAPR) Trading Signals - Stock Traders Daily
Capricor projects FDA priority review decision for deramiocel by August 2025 - MSN
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2024 Earnings Call Transcript - Insider Monkey
Capricor Therapeutics’ Earnings Call Highlights Progress and Challenges - TipRanks
Capricor Therapeutics Inc (CAPR) Q4 2024: Everything You Need To Know Ahead Of Earnings - GuruFocus.com
Capricor Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance
Is Capricor Therapeutics (CAPR) a Worst High-Risk High-Reward Growth Stock to Buy? - Insider Monkey
Jabil Posts Better-Than-Expected Earnings, Joins Darden Restaurants, QXO, Five Below And Other Big Stocks Moving Higher On Thursday - Benzinga India
Cantor Fitzgerald maintains $30 target on Capricor stock By Investing.com - Investing.com South Africa
Cantor Fitzgerald maintains $30 target on Capricor stock - Investing.com
A Glimpse Into The Expert Outlook On Capricor Therapeutics Through 4 Analysts - Benzinga
Capricor Therapeutics Stock (CAPR) Surges on Q4 Results and Promising New Therapy - The Globe and Mail
Capricor Therapeutics Reports 2024 Financial Results - TipRanks
Capricor: Q4 Earnings Snapshot - mySA
Earnings call transcript: Capricor Q4 2024 beats EPS forecast, stock up - Investing.com Canada
Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Capricor Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Capricor Therapeutics Inc Reports Q4 2024 Earnings: EPS Loss of - GuruFocus.com
Capricor Therapeutics Q4 Loss Widens, Revenue Decreases -March 19, 2025 at 04:39 pm EDT - Marketscreener.com
Capricor Therapeutics beats Q4 estimates, shares rise on FDA acceptance By Investing.com - Investing.com Canada
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - TradingView
Capricor Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Capricor's DMD Breakthrough: FDA Fast-Tracks Novel Therapy as Cash Position Hits $151.5M - StockTitan
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Shares May Have Slumped 27% But Getting In Cheap Is Still Unlikely - Simply Wall St
While institutions own 38% of Capricor Therapeutics, Inc. (NASDAQ:CAPR), retail investors are its largest shareholders with 49% ownership - Yahoo Finance
Capricor Therapeutics announces long-term data from HOPE-2 OLE study - Yahoo Finance
H.C. Wainwright maintains Capricor stock Buy rating and $77 target By Investing.com - Investing.com UK
Capricor Therapeutics’ (CAPR) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
CAPRICOR THERAPEUTICS Earnings Preview: Recent $CAPR Insider Trading, Hedge Fund Activity, and More - Nasdaq
Capricor Therapeutics Announces Positive Data Demonstrating - GlobeNewswire
Capricor reports promising DMD treatment results - Investing.com
Capricor Therapeutics Says 3-Year Data Show Deramiocel Slows Duchenne Muscular Dystrophy - Marketscreener.com
Capricor reports promising DMD treatment results By Investing.com - Investing.com Australia
Capricor Therapeutics Reports 52% Slowing of Duchenne Muscular Dystrophy Disease Progression with Deramiocel in 3-Year Study Presentation at MDA Conference - Nasdaq
Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy - Yahoo Finance UK
Breakthrough: New DMD Drug Cuts Disease Progression in Half Over 3 Years - StockTitan
When the Price of (CAPR) Talks, People Listen - Stock Traders Daily
Capricor touts long-term efficacy of DMD therapy ahead of FDA application - MSN
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) Price Target at $34.50 - Defense World
Brokerages Set Capricor Therapeutics Inc (NASDAQ:CAPR) PT at $34.50 - Armenian Reporter
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition - AOL
Capricor at Leerink’s Conference: Strategic Moves in Cell Therapy By Investing.com - Investing.com UK
Rare Disease Biotech Capricor Therapeutics Announces Critical Year-End Earnings Date - StockTitan
Capricor Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 19, 2025 - Nasdaq
Capricor Therapeutics to Present Fourth Quarter and Full - GlobeNewswire
Capricor Therapeutics receives FDA acceptance of BLA for deramiocel - TipRanks
Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA - Marketscreener.com
Capricor Therapeutics Inc Azioni (CAPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):